Liminatus Pharma Joins Forces with Samda Biolab and INNOCS AI to Develop Groundbreaking Pancreatic Cancer Diagnostic Kit

Reuters

2025/07/03

Liminatus Pharma Joins Forces with Samda Biolab and INNOCS AI to Develop Groundbreaking Pancreatic Cancer Diagnostic Kit

Liminatus Pharma Inc. has announced a strategic partnership through a Memorandum of Understanding to form a research and development consortium with Samda Biolab Co., Ltd. and INNOCS AI. This collaboration aims to advance a novel blood-based diagnostic kit for early detection of pancreatic cancer. Leveraging INNOCS AI's artificial intelligence technology and Samda's biomarker platform, alongside Liminatus Pharma's regulatory and commercial expertise, the partnership seeks to enhance corporate value and establish a strong foothold in the precision oncology diagnostics market. This initiative is seen as a critical milestone towards transforming cancer care and is expected to position Liminatus Pharma as a leader in metabolomics-driven cancer diagnostics. The consortium's innovative approach has demonstrated high sensitivity and specificity in recent clinical data, underscoring its potential impact on the global pancreatic cancer diagnostics market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-065663), on July 03, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2548386823"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548386823\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548386823?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-03 23:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548386823","market":"us","top_or_hot":-1,"title":"Liminatus Pharma Joins Forces with Samda Biolab and INNOCS AI to Develop Groundbreaking Pancreatic Cancer Diagnostic Kit","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Liminatus Pharma Joins Forces with Samda Biolab and INNOCS AI to Develop Groundbreaking Pancreatic Cancer Diagnostic Kit\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Liminatus Pharma Inc. has announced a strategic partnership through a Memorandum of Understanding to form a research and development consortium with Samda Biolab Co., Ltd. and INNOCS AI. This collaboration aims to advance a novel blood-based diagnostic kit for early detection of pancreatic cancer. Leveraging INNOCS AI's artificial intelligence technology and Samda's biomarker platform, alongside Liminatus Pharma's regulatory and commercial expertise, the partnership seeks to enhance corporate value and establish a strong foothold in the precision oncology diagnostics market. This initiative is seen as a critical milestone towards transforming cancer care and is expected to position Liminatus Pharma as a leader in metabolomics-driven cancer diagnostics. The consortium's innovative approach has demonstrated high sensitivity and specificity in recent clinical data, underscoring its potential impact on the global pancreatic cancer diagnostics market.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-065663), on July 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liminatus Pharma Joins Forces with Samda Biolab and INNOCS AI to Develop Groundbreaking Pancreatic Cancer Diagnostic Kit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiminatus Pharma Joins Forces with Samda Biolab and INNOCS AI to Develop Groundbreaking Pancreatic Cancer Diagnostic Kit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-03 23:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Liminatus Pharma Joins Forces with Samda Biolab and INNOCS AI to Develop Groundbreaking Pancreatic Cancer Diagnostic Kit\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Liminatus Pharma Inc. has announced a strategic partnership through a Memorandum of Understanding to form a research and development consortium with Samda Biolab Co., Ltd. and INNOCS AI. This collaboration aims to advance a novel blood-based diagnostic kit for early detection of pancreatic cancer. Leveraging INNOCS AI's artificial intelligence technology and Samda's biomarker platform, alongside Liminatus Pharma's regulatory and commercial expertise, the partnership seeks to enhance corporate value and establish a strong foothold in the precision oncology diagnostics market. This initiative is seen as a critical milestone towards transforming cancer care and is expected to position Liminatus Pharma as a leader in metabolomics-driven cancer diagnostics. The consortium's innovative approach has demonstrated high sensitivity and specificity in recent clinical data, underscoring its potential impact on the global pancreatic cancer diagnostics market.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-065663), on July 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDL8VCpHG:1","article_id":"2548386823","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548386823","pubTimestamp":1751557280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Liminatus Pharma Inc. has announced a strategic partnership through a Memorandum of Understanding to form a research and development consortium with Samda Biolab Co., Ltd. and INNOCS AI. This collaboration aims to advance a novel blood-based diagnostic kit for early detection of pancreatic cancer. Leveraging INNOCS AI's artificial intelligence technology and Samda's biomarker platform, alongside Liminatus Pharma's regulatory and commercial expertise, the partnership seeks to enhance corporate value and establish a strong foothold in the precision oncology diagnostics market. This initiative is seen as a critical milestone towards transforming cancer care and is expected to position Liminatus Pharma as a leader in metabolomics-driven cancer diagnostics. The consortium's innovative approach has demonstrated high sensitivity and specificity in recent clinical data, underscoring its potential impact on the global pancreatic cancer diagnostics market.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LIMN":"Liminatus Pharma LLC"},"translate_title":"Liminatus Pharma与Samda Biolab和INNOCS AI联手开发突破性胰腺癌诊断试剂盒","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIMN":0.9},"content_text":"Liminatus Pharma Joins Forces with Samda Biolab and INNOCS AI to Develop Groundbreaking Pancreatic Cancer Diagnostic Kit\n    \n\n        Liminatus Pharma Inc. has announced a strategic partnership through a Memorandum of Understanding to form a research and development consortium with Samda Biolab Co., Ltd. and INNOCS AI. This collaboration aims to advance a novel blood-based diagnostic kit for early detection of pancreatic cancer. Leveraging INNOCS AI's artificial intelligence technology and Samda's biomarker platform, alongside Liminatus Pharma's regulatory and commercial expertise, the partnership seeks to enhance corporate value and establish a strong foothold in the precision oncology diagnostics market. This initiative is seen as a critical milestone towards transforming cancer care and is expected to position Liminatus Pharma as a leader in metabolomics-driven cancer diagnostics. The consortium's innovative approach has demonstrated high sensitivity and specificity in recent clinical data, underscoring its potential impact on the global pancreatic cancer diagnostics market.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-065663), on July 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}